LABORIE completed its agreement with UroMed Technology, Inc. to acquire their Pelvic Muscle Rehabilitation business. UroMed Technology, Inc. develops, manufactures and distributes innovative and advanced biofeedback and electrical stimulation equipment, accessories and consumables for pelvic floor dysfunction in the treatment of Urinary and Fecal Incontinence.
“This acquisition strengthens our foundation in Pelvic Muscle Rehabilitation and expands our presence in the conservative therapy sector by offering brands that are synonymous with innovation and quality”, stated Brian Ellacott, President and CEO. “Both LABORIE and UroMed Technology, Inc. have a shared commitment to helping healthcare professionals deliver better products and services, and to make life more rewarding and dignified for those who use our products. By combining existing product lines with our extensive customer base, we can provide greater support and commitment to customers worldwide.”
LABORIE (www.laborie.com), headquartered in Toronto, Canada, is a leading global developer, manufacturer and marketer of innovative medical technology and consumables used for the diagnosis and treatment of Urinary and Fecal Incontinence, as well as other pelvic floor disorders in the Urology, Gynecology, and Colorectal fields.
LABORIE Medical Technologies (“LABORIE”) and Cogentix Medical, Inc. (NASDAQ: CGNT) (“Cogentix”) today announced the completion of the acquisition by LABORIE of Cogentix through LABORIE’S affiliate Camden Merger Sub, Inc. (“Merger Sub”), a wholly owned subsidiary of LM US Parent, Inc. (“Parent”).
LABORIE Medical Technologies (“LABORIE”) announced the successful completion of the tender offer by its affiliate Camden Merger Sub, Inc. (“Merger Sub”), a wholly owned subsidiary of LM US Parent, Inc. (“Parent”) to purchase all outstanding shares of common stock of Cogentix Medical, Inc. (NASDAQ: CGNT) (“Cogentix”)
LABORIE Medical Technologies, a leading global developer and manufacturer of medical diagnostics and devices in the pelvic health and gastroenterology market, today announces the execution of a definitive agreement to acquire Cogentix Medical Inc., (NASDAQ: CGNT)